Pharma

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about Zantac court cases, a Neurocrine schizophrenia pill, and more

The Readout Elaine Chen

STAT Plus: Hims takes a blow from Lilly’s vial news

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about Lilly cutting Zepbound’s price; Pfizer selling direct to consumers, and more

The Readout Elaine Chen

STAT Plus: Pfizer and Lilly want to sell you drugs directly

Health tech Katie Palmer

STAT Plus: To help migraine patients — and sell more medicines — major drugmakers turn to telehealth

The Readout Meghana Keshavan

STAT Plus: A Galapagos investor signals impatience with its turnaround efforts

Pharmalot Adam Feuerstein

STAT Plus: Pharmalittle: UCB selling a Chinese business, Tome layoffs, and more

Pharmalot Ed Silverman

STAT Plus: U.S. agency slaps down a J&J plan to switch payments for 340B hospitals

Pharmalot Ed Silverman

STAT Plus: Up and down the ladder: The latest comings and goings

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about AstraZeneca threatening the U.K., mpox vaccine distribution, and more

Pharmalot Adam Feuerstein

STAT Plus: Pharmalittle: We’re reading about a negative U.K. review of Leqembi, Bavarian Nordic’s strong earnings, and more

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about obesity drugs and suicidal thoughts, a FDA official’s conflicts, and more

Health tech Mohana Ravindranath

STAT Plus: Carbon Health founder steps back from top role, Kaiser hospitals roll out AI scribe

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about Zepbound trial results, an Alnylam heart drug, and more

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about FTC scrutiny of a Novo deal, a Genentech reorganization, and more

Pharmalot Ed Silverman

STAT Plus: Will the FTC challenge a deal that would give Novo Nordisk control of some Catalent plants?

Pharmalot Ed Silverman

STAT Plus: Up and down the ladder: The latest comings and goings

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about a Covid-flu shot setback, mpox vaccine supplies, and more

The Readout Meghana Keshavan

STAT Plus: Is pharma still fearful of the Inflation Reduction Act?

Politics Rachel Cohrs Zhang

STAT Plus: What do Biden’s drug price comparisons reveal? Not much

Health Jason Mast

STAT Plus: Antiviral used for mpox no better than placebo, NIH says

The Readout Elaine Chen

STAT Plus: We have mpox vaccines now. But how will they be distributed?

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about Medicare drug savings, Lilly warning doctors, and more

Politics John Wilkerson and Rachel Cohrs Zhang

STAT Plus: Medicare drug price negotiation didn’t benefit Biden — but it may help Harris

Pharma Rachel Cohrs Zhang

STAT Plus: Medicare announces drug prices for historic first round of negotiations

Pharma Joseph Howlett and Andrea Tamayo

STAT Plus: Arthritis patients resort to an inconvenient Medicare workaround to avoid pricey drugs

Biotech Matthew Herper

STAT Plus: Eli Lilly’s billions: Can the world’s most valuable pharma company keep inventing drugs at this pace?

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about an AstraZeneca U.K. vaccine plant, Medicare premiums, and more

The Readout Elaine Chen

STAT Plus: Syros shares battered after it stops leukemia trial